A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : TG101348
Phase: Phase 1
Ages Eligible For Study:
- Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia) - At least 18 years of age. - ECOG PS 0, 1, or 2.